Consider Trelegy a Last-Line Option for COPD

January 2018

Trelegy Ellipta (TREL-eh-gee) will be the first "three-in-one" inhaler for COPD.

It contains the long-acting muscarinic antagonist (LAMA) umeclidinium...the long-acting beta-agonist (LABA) vilanterol...and the inhaled corticosteroid (ICS) fluticasone furoate.

Trelegy is a dry-powder inhaler given as a single puff once daily.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

12 issues every year, with brief articles about new meds and guidelines
48+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Hypertension Re-Evaluate Blood Pressure Goals With New Hypertension Guidelines
Hypertension Reinforce Techniques for Accurate Blood Pressure Readings
Diabetes Meds Don't Rule Out Sulfonylureas for Type 2 Diabetes
Influenza Consider When To Use Antivirals to Treat the Flu
Cough & Cold Avoid Pitfalls With Cough Meds
Hypothyroidism Be Prepared to Answer Common Questions About Hypothyroidism
Med Safety Educate Patients on Meds Linked to Impaired Driving
Substance Use Disorder Think About Naltrexone for Opioid Dependence in Some Patients
Topicals Be Ready With Lower-Cost Topical Steroid Options
COPD Consider Trelegy a Last-Line Option for COPD

Consider Trelegy a Last-Line Option for COPD

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Table of Contents